On 20 February 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) released an updated version of its guidance on registering medical devices for placement on the market in Great Britain (GB) and Northern Ireland (NI). At first glance, the update reads like a routine maintenance release. In practice, it signals a meaningful shift in how manufacturers and authorized representatives will need to manage registrations, particularly where Northern Ireland alignment with EU systems is concerned. The changes also introduce a recurring fee structure and expand public visibility into registered devices, both of which will have operational consequences inside regulatory and compliance teams.
For companies that have grown comfortable with the post-Brexit steady state, this update is a reminder that the UK framework is still evolving. The guidance does not fundamentally rewrite market access pathways, but it does tighten expectations and close several areas that previously allowed for interpretive flexibility. Organizations that treat this as a minor administrative update risk being caught off guard when the new requirements begin to take effect over the coming months.
A Structural Shift in Northern Ireland Registration
The most consequential change centers on Northern Ireland. Beginning 28 May 2026, most non-custom-made medical devices must be registered in the European Database on Medical Devices (EUDAMED) before they can be placed on the EU or Northern Ireland markets. Once this requirement takes effect, MHRA registration will no longer be required for those devices in NI. This effectively deepens Northern Ireland’s regulatory alignment with the EU framework, even as Great Britain continues to operate under its own domestic system.
In practical terms, this creates a bifurcated registration strategy that many organizations will need to formalize. Regulatory teams that previously treated UK registration as a largely unified process must now build workflows that distinguish clearly between GB and NI obligations. Companies that already maintain robust EU MDR or IVDR processes will be better positioned, but even they should expect some internal friction as responsibilities shift. Where a single regulatory owner once handled UK submissions, organizations may now need tighter coordination between EU and UK specialists to avoid gaps or duplicate effort.
Custom-made devices remain the notable exception. Because they fall outside the scope of EUDAMED, these products must continue to be registered with MHRA for Northern Ireland. This carve-out may seem narrow, but it introduces the kind of edge case that often creates confusion during audits or portfolio reviews. Manufacturers with mixed product portfolios should pay particular attention to how their internal classification logic distinguishes custom-made devices from standard products.
The Move to Annual Registration Fees
Effective 1 April 2026, MHRA will implement an annual registration fee structure, replacing the previous one-time model. Fees will be calculated based on the number of Global Medical Device Nomenclature (GMDN) Level 2 categories associated with a manufacturer’s registrations. While the concept of recurring fees is not unusual globally, the shift will require companies to revisit how carefully they maintain their GMDN mappings.
Inside many organizations, GMDN assignment has historically been treated as a one-time classification exercise performed during initial market entry. Under the new model, that approach becomes risky. Over-classification could inflate annual costs, while inaccurate mappings could trigger MHRA scrutiny or even account suspension. Regulatory affairs teams will likely need to collaborate more closely with product management and labeling functions to ensure category assignments remain precise as portfolios evolve.
Finance teams will also feel the impact. Budgeting for UK market maintenance will no longer be a static line item tied only to new product introductions. Instead, it becomes an ongoing operational expense that scales with portfolio breadth. Companies with large device families may want to model their exposure early to avoid surprises in the next fiscal planning cycle.
EUDAMED as the Gatekeeper for NI Market Access
The formalization of EUDAMED as a prerequisite for most NI placements marks an important policy signal. It reinforces the UK’s intention to maintain a distinct GB framework while allowing Northern Ireland to remain closely integrated with EU device oversight. For manufacturers, the practical implication is straightforward: if EUDAMED data is incomplete or delayed, NI market access will be directly affected.
This is where execution discipline will matter. Many organizations still treat EUDAMED submissions as a compliance milestone rather than a living data obligation. In reality, the system increasingly functions as an operational backbone for EU-aligned markets. Companies that invest in clean, well-governed EUDAMED data flows will experience fewer downstream disruptions. Those that rely on manual uploads or fragmented data ownership may find themselves troubleshooting avoidable delays just as the May 2026 deadline approaches.
Clarified Expectations for IVD Performance Evaluations
The updated guidance also removes ambiguity around in vitro diagnostic devices undergoing performance evaluation in the UK. These IVDs must be registered with MHRA before study initiation. While this requirement was broadly understood by experienced regulatory teams, the clarification signals MHRA’s intent to enforce the expectation more consistently.
In practice, this will most affect organizations running early-stage clinical or performance workstreams. Study teams sometimes move quickly once protocols are approved, assuming registration steps can be finalized in parallel. Under the clarified guidance, that sequencing becomes risky. Regulatory leads should ensure that study startup checklists explicitly include MHRA registration verification to avoid delays or compliance findings during inspections.
CTDA Validation Remains a Hard Gate for COVID-19 Tests
For COVID-19 antigen and molecular (PCR) tests, the guidance reiterates that devices must obtain validation under the Coronavirus Test Device Approval (CTDA) or be listed under the relevant protocol before MHRA registration applications will be accepted. Although the volume of new COVID-19 test submissions has declined from pandemic peaks, the requirement remains firmly in place.
This is particularly relevant for manufacturers maintaining legacy COVID-19 portfolios or introducing next-generation respiratory panels that include SARS-CoV-2 targets. Teams sometimes assume the regulatory intensity around COVID-19 products has softened. The continued CTDA gate makes clear that MHRA still expects a defined validation pathway before market registration proceeds.
Expanded Public Transparency Through PARD
Another notable update took effect on 23 February 2026, when the Public Access Registration Database (PARD) began displaying brand and trade names of registered medical devices. This change may appear administrative, but it materially increases the visibility of device portfolios to competitors, healthcare providers, and the public.
Greater transparency tends to surface data quality issues that previously went unnoticed. If brand names are inconsistent across submissions, or if legacy registrations contain outdated product information, those discrepancies are now easier to spot. Organizations would be wise to conduct a portfolio hygiene review rather than assuming their historical entries will withstand public scrutiny.
There is also a reputational dimension. Public databases increasingly serve as informal due-diligence tools for distributors and procurement teams. Clean, consistent listings can reinforce credibility, while messy or incomplete records can raise questions that slow commercial conversations. Regulatory accuracy and commercial perception are becoming more tightly linked.
What the Timeline Really Means for Manufacturers
The sequencing of the changes is deliberate. Public database enhancements arrived first in February 2026, followed by annual fees in April and the EUDAMED requirement for NI in late May. This staggered rollout gives manufacturers time to adjust, but only if they start planning now.
Organizations that wait until each deadline is imminent will likely experience avoidable friction whether in the form of rushed GMDN reviews, last-minute EUDAMED data remediation, or unexpected budget pressure from the new fee model. By contrast, companies that treat the update as a coordinated program of work can absorb the changes with relatively little disruption.
Conclusion
The February 2026 MHRA guidance update does not introduce a single headline-grabbing reform. Instead, it tightens multiple parts of the UK device registration ecosystem at once. Northern Ireland alignment with EUDAMED, the shift to annual fees, and expanded public transparency all point in the same direction: more continuous oversight and less tolerance for passive compliance.
For experienced regulatory teams, the path forward is manageable but requires intentional preparation. The organizations that will navigate this transition most smoothly are those that treat registration data as a living asset, maintain disciplined GMDN governance, and proactively align their GB and NI strategies. The guidance may read like an incremental update, but operationally, it rewards companies that are paying close attention.
